Earnings (Loss) per share	3 Months Ended
Mar. 31, 2025
Earnings (Loss) per share	NOTE 13 – Earnings (Loss) per share: Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (“RSUs”) and performance share units (“PSUs”) during the period, net of treasury shares. In computing diluted earnings per share for the three months ended March 31, 2025, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share. In computing diluted loss per share for the three months ended March 31, 2024, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended March 31, 2025 and 2024 were 1,159 million shares and 1,123 million shares, respectively. Basic earnings per share was $0.19 for the three months ended March 31, 2025, compared to basic loss per share of $0.12 for the three months ended March 31, 2024. Diluted earnings per share was $0.18 for the three months ended March 31, 2025, compared to diluted loss per share of $0.12 for the three months ended March 31, 2024.

Earnings (Loss) per share

3 Months Ended

Mar. 31, 2025

NOTE 13 – Earnings (Loss) per share:

Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested restricted share units (“RSUs”) and performance share units (“PSUs”) during the period, net of treasury shares.

In computing diluted earnings per share for the three months ended March 31, 2025, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and

non-vested

RSUs and PSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share.

In computing diluted loss per share for the three months ended March 31, 2024, no account was taken of the potential dilution that could occur upon the exercise of options and

non-vested

RSUs and PSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share.

The weighted average diluted shares outstanding used for the fully diluted share calculations for the three months ended March 31, 2025 and 2024 were 1,159 million shares and 1,123 million shares, respectively.

Basic earnings per share was $0.19 for the three months ended March 31, 2025, compared to basic loss per share of $0.12 for the three months ended March 31, 2024.

Diluted earnings per share was $0.18 for the three months ended March 31, 2025, compared to diluted loss per share of $0.12 for the three months ended March 31, 2024.